- Lennart Waldenlind, pharmacovigilance assessor1,
- Birgitta Grundmark, pharmacovigilance assessor12,
- Faranak Azarbayjani, pharmacovigilance assessor13,
- Andreas Börjesson, pharmacovigilance assessor1,
- Hans Olaisson, pharmacovigilance assessor1
- 1Department of Pharmacovigilance, Medical Products Agency, PO Box 26, SE-751 03 Uppsala, Sweden
- 2Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
- 3Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
- lennart.waldenlind{at}mpa.se
In line with previous studies, Miller and colleagues find an increased risk of narcolepsy after vaccination with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix; odds ratio 16.2, 95% CI 3.1 to 84.5) and call for similar studies on other flu vaccines.1
Several flu vaccines are available in Europe, both adjuvanted and non-adjuvanted. All suspected adverse vaccine reactions must be reported to pan-European database EudraVigilance (www.adrreports.eu), which will soon be fully publicly accessible. The first suspected case of narcolepsy associated with a non-adjuvanted flu …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.